The CAPItello-291 Trial: Final Overall Survival Results of Capivasertib and Fulvestrant in HR+/HER2− Advanced Breast Cancer

Professor Hope S. Rugo discusses the final overall survival results from the Phase 3 CAPItello-291 trial, evaluating the efficacy, long-term disease control, and safety of combining the AKT inhibitor capivasertib with fulvestrant for patients with AI-resistant, HR+/HER2− advanced breast cancer.

Immunotherapy in Early-Stage Breast Cancer - Report from ESMO BC 2026

Professor Giampaolo Bianchini discusses the evolving landscape of immunotherapy in early-stage breast cancer, focusing on predictive biomarkers, patient selection, and the integration of checkpoint inhibitors into neoadjuvant and adjuvant treatment settings to improve long-term outcomes.

Program Director's Choice from SABCS2025 - Part 1 : Giredestrant Improves Disease-free Survival in Patients With Early-stage Breast Cancer in Phase III lidERA Trial

Kate Lathrop, MD discuss one of the high impact, clinically relevant, clinical trial, the lidERA trial that were presented at the San Antonio Breast Cancer Symposium 2025.

Program Director's Choice from SABCS2025 - Part 2: Sacituzumab Govitecan for Endocrine Therapy-refractory Advanced Breast Cancers

Kate Lathrop, MD discuss one of the high impact, clinically relevant, clinical trial, the ASCENT-07 trial that were presented at the San Antonio Breast Cancer Symposium 2025.

Program Director's Choice from SABCS2025 - Part 3: Adding Tucatinib to First-line Maintenance Therapy Delayed Disease Progression in HER2-positive Metastatic Breast Cancer in HER2CLIMB-05 Trial

Kate Lathrop, MD discuss one of the high impact, clinically relevant, clinical trial, the HER2CLIMB-05 trail that were presented at the San Antonio Breast Cancer Symposium 2025.

Highligths of SABCS 2025

Prof. Virginia G. Kaklamani discuss some of the high impact, clinically relevant, clinical trials that were presented at the San Antonio Breast Cancer Symposium 2025, like the lidERA, HER2CLIMB-05 and WISDOM trial.

Modulating the Tumor Microenvironment with T Cell Bispecifics

Professor Sumit K. Subudhi shares his insights on modulating the tumor microenvironment with T Cell bispecifics at SITC's 40th Anniversary Annual Meeting.

How to optimize PD1/PDL1 treatment?

Professor Gordon J. Freeman shares his insights on how to optimize PD1/PDL1 treatment at SITC's 40th Anniversary Annual Meeting.

Phase I Trial of DOC1021 Cell-Based Immunotherapy for Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma

Professor William Decker discusses the Phase I Trial of DOC1021 cell-based immunotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma at SITC's 40th Anniversary Annual Meeting.

Primary analysis of patients with high-risk localized, locally recurrent, or regionally advanced cutaneous squamous cell carcinoma treated with neoadjuvant PD-1 therapy

Professor Gino In presented data from the NeoPOWER trial, to study the role of neoadjuvant PD-1 alone in CSCC at SITC's 40th Anniversary Annual Meeting.

Reprogramming the Immune Microenvironment to Intercept Lung Adenocarcinoma Precancer

Professor Jianjun Zhang shares his insights on reprogramming the immune microenvironment to intercept lung adenocarcinoma precancer at SITC's 40th Anniversary Annual Meeting.

State of the art tumor-targeting IL-12 immunocytokine therapies

Dr. Gregory Conn shares his insights on state of the art tumor-targeting IL-12 immunocytokine therapies after SITC's 40th Anniversary Annual Meeting.

What's new in ESMO guidelines?

Professor Emanuela Romano explains what's new in ESMO guidelines on hepatocellular carcinoma, cutaneous melanoma, Hodgkin Lymphomas and early stage and locally advanced non-small cell lung cancers at the ESMO Congress 2025.

T-DXd Effective for Treating HER2+ Advanced or Metastatic Breast Cancer, Regardless of Treatment History, HR Status, or PIK3C Mutations

Professor Sibylle Loibl shares her thoughts on the additional analyses of DESTINY-Breast09 were presented at the ESMO Congress 2025. Key subgroup analysis of DESTINY-Breast09 confirms efficacy of trastuzumab deruxtecan plus pertuzumab for treating HER2+ advanced or metastatic breast cancer across groups. 

IMvigor011: A Phase 3 Trial of ctDNA-Guided Adjuvant Atezolizumab versus Placebo in MIBC

Professor Thomas B. Powles discuss the results from IMvigor011, a phase 3 trial of ctDNA-guided adjuvant atezolizumab versus placebo in muscle invasive bladder cancer were presented at the ESMO Congress 2025.

How to PROC - Breaking the Wall of Platinum-Resistance in Ovarian Cancer

Professor Jalid Sehouli explains how to break the wall of platinum-resistance in ovarian cancer at the ESMO Congress 2025.

Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women

Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the Phase III SOLAR-1 trial

Lifestyle Intervention Helped Breast Cancer Survivors Lose Weight, and Was Associated with Higher Disease-free Survival Rates

Choice of Surgery May Affect Quality of Life for Young Breast Cancer Survivors

Circulating Tumor Cell Count Could Help Choose Treatment for Metastatic Breast Cancer Patients

Axillary Radiotherapy and Lymph Node Surgery Yielded Comparable 10-year Outcomes for Patients with Breast Cancer

Accelerated Partial Breast Irradiation, Although Close, was Not Equivalent to Whole Breast Irradiation To Control Ipsilateral Breast Tumor Recurrence

A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ

PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib

Phase III KATHERINE Clinical Trial Crossed Early Reporting Boundary and Met its Primary Endpoint

Adjuvant Capecitabine Did Not Significantly Improve Outcomes for Patients With Early-stage Triple-negative Breast Cancer

Adjuvant Chemotherapy Might Not Add Benefit in Breast Cancer Patients who Have Excellent Response to Neoadjuvant Chemotherapy

Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer

Low-Dose Tamoxifen Was Safe and Effective at Reducing Recurrence and New Breast Disease for Patients With DCIS, LCIS, and ADH

Increasing the dose intensity of adjuvant chemotherapy: an EBCTCG meta-analysis

Phase Ib/II Study Evaluating Safety and Efficacy of Pembrolizumab and Trastuzumab in Patients with Trastuzumab-Resistant HER2-positive Advanced Breast Cancer: Results from the PANACEA Study (IBCSG 45-13/BIG 4-13/KEYNOTE-014)